Shire’s potential blockbuster Xiidra (lifitegrast) has been approved in the US for dry eye disease, bouncing back from a rejection by the regulator late last year. Xiidra, in a 5% solution ...

The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis. Novartis paid Takeda $3.4 ...